Ask Warren

Hanmi Pharm

128940 · KOSPI · ₩128940 · 한미약품

₩388,500▲ ₩19,000 (5.14%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −1.27%
Market cap
₩5T
Enterprise value
₩4.8T
P/E
22.9×
P/B
3.5×
Dividend yield
0.5%
ROE
15.5%
Net margin
13.1%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−40.0% from the high

₩302,000Today: ₩375,500 – ₩393,000₩647,000

Returns

  • 1W+4.9%
  • 1M−23.4%
  • 3M+24.7%
  • 6M−15.5%
  • YTD−14.0%
  • 1Y−1.3%
Volume today
163,257
1.5× the 20-day average
Traded today
₩63B
Listed shares
12,810,991
EPS (12 months)
₩16,942
Earnings yield 4.4%
SellBuy
AI research · Update noteHanmi Pharm Q3 2026 Preliminary Results: Operating Profit Falls 31.3% Year on YearThe Q3 result is a clear negative for the earnings-improvement story: profit fell sharply while revenue grew modestly, and the cause is not given.Read the full report →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Why is it moving?

+5.1% on Oct 29, 2026.

Hanmi Pharm signed a technology export deal with US firm BioMarin for a Fabry disease drug, worth up to $475 million, shared with GC Biopharma. The shares rose more than 8% on the news, and investors also cite hopes for its obesity drug.

AI summary of the news and filings linked. It can be wrong; check them.

Possible reasons, not certainties. Not financial advice.

Signals

57Normal
  • BuzzNormalBuzz 57: in the news.
  • SentimentPositiveNews: Big technology export deal and strong share rise, though a management dispute is also in the headlines. Community: 0 bullish, 0 bearish posts this week.
  • MomentumWeak-22.9% over the last month; the price is below its 20-day average.
  • News impactHigh41 news items and filings in two weeks; 2 rated high impact, 22 medium.
  • StreetTargets going down3 brokers, average target 72% from the price; last 30 days: 0 raised, 1 cut.

Signals describe activity, not recommendations. Not financial advice.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Oct 29: sell ₩156M at the close (0.3% of 20-day average trading value)

Sep 30Last 20 trading days (% of average trading value)Oct 29

On its 24 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 1.6% of trading value and pointed the same way 11 of 24 times.

  • -2× KODEX 200 Futures Inverse 2X −₩111M
  • 2× KODEX Leverage −₩13M
  • 2× TIGER 200IT Leverage −₩7.5M
  • -1× KODEX Inverse −₩6.6M
  • 2× TIGER Leverage −₩5.2M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

ETFs holding this

All ETFs →

Held by 32 funds.

Estimated from the funds' index or underlying stock.

Futures and options

All stock futures →

Futures (2026-11): 389,000

Basis +0.13% · implied rate +3.4%

Open interest 9,115 contracts

Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.

Hanmi Pharm stock overview

Hanmi Pharm (한미약품, KRX: 128940) is listed on KOSPI, in the Biotech & Pharma sector. Hanmi Pharmaceutical manufactures and sells pharmaceuticals through three segments: pharmaceuticals, active pharmaceutical ingredients (APIs), and overseas pharmaceuticals. Its shares closed at ₩388,500 on Oct 29, 2026, up 5.14% on the day, giving it a market value of ₩5T.

Key facts

Market cap
₩5T
Sector
Biotech & Pharma
Latest price change
+5.14%
As of
Oct 29, 2026
Main business
Hanmi Pharmaceutical manufactures and sells pharmaceuticals through three segments: pharmaceuticals, active pharmaceutical ingredients (APIs), and overseas pharmaceuticals.

Quick answers about Hanmi Pharm

What does Hanmi Pharm do?
Hanmi Pharmaceutical manufactures and sells pharmaceuticals through three segments: pharmaceuticals, active pharmaceutical ingredients (APIs), and overseas pharmaceuticals. Its main products include the hypertension combination drug Amosartan, the lipid-lowering drug Rosuzet, the reflux esophagitis treatment Esomezol, and the erectile dysfunction drug Palpal, and it focuses on R&D for innovative new drugs. Hanmi Fine Chemical supplies APIs, especially cephalosporin antibiotics, to multinational pharmaceutical companies and exports to about 40 countries, while Beijing Hanmi Pharmaceutical sells children's and adult digestive remedies and cough medicines in China.
What is the market cap of Hanmi Pharm?
The market capitalisation of Hanmi Pharm was ₩5T at the close on Oct 29, 2026.
What is the analyst target price for Hanmi Pharm?
The average target price of 3 brokers covering Hanmi Pharm is ₩666,667 (range ₩600,000 to ₩700,000), 71.6% above versus the latest price, based on each broker's latest public report within six months.
Who are the largest shareholders of Hanmi Pharm?
According to the latest official filings, the largest reported holders are Hanmi Science (49.55%, as of Sep 29, 2026); National Pension Service (10.15%, as of Oct 6, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (0.71%, as of Jul 31, 2026).
When is the next earnings report from Hanmi Pharm?
Korean companies rarely announce results dates in advance. Based on when Hanmi Pharm filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Does the National Pension Service own Hanmi Pharm?
Yes. The National Pension Service held 9.61% of Hanmi Pharm shares as of Oct 2, 2026.

Company profile

Hanmi Pharmaceutical manufactures and sells pharmaceuticals through three segments: pharmaceuticals, active pharmaceutical ingredients (APIs), and overseas pharmaceuticals. Its main products include the hypertension combination drug Amosartan, the lipid-lowering drug Rosuzet, the reflux esophagitis treatment Esomezol, and the erectile dysfunction drug Palpal, and it focuses on R&D for innovative new drugs. Hanmi Fine Chemical supplies APIs, especially cephalosporin antibiotics, to multinational pharmaceutical companies and exports to about 40 countries, while Beijing Hanmi Pharmaceutical sells children's and adult digestive remedies and cough medicines in China.

Written by AI from the company's latest annual report.

Korean name
한미약품
Sector
Biotech & Pharma
Themes
Biotech (new drugs)Contract drug manufacturing (CDMO)Obesity drugsADC & cancer drugsPharmaceuticals
CEO
황상연
Founded
Jul 2010
Listed
Jul 2010
Listed shares
12,810,991
Fiscal year ends
Month 12
Website
-

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Creators talking about this

Also known as: Hanmi Pharm / 한미약품 / 128940 / KRX:128940

Source: KRX statistical information